NEW YORK (GenomeWeb News) – Response Genetics' second-quarter revenues plummeted 76 percent year over year on a drop-off in the company's pharmaceutical client sales, the Los Angeles-based molecular diagnostics firm reported today.

Total revenues for the three months ended June 30 were $3.8 million, compared to $6.7 million a year ago. While ResponseDX revenue fell $151,000 from a year ago, pharmaceutical client revenue fell by more than $2.7 million from a year ago, the firm said, adding that the drop was expected.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.